STOCK TITAN

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 p.m. ET. This event will showcase Annexon's efforts in developing a new class of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event.

Annexon focuses on therapies targeting the classical complement pathway, a key immune system mechanism. The company is advancing a pipeline of product candidates and expects to release clinical data throughout 2023.

Loading...
Loading translation...
Argus Session date unavailable
+5.95% session move Open Argus
Details

News Market Reaction – ANNX

The recorded move for ANNX in the trading session of this news was +5.95%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late-stage clinical trials, with clinical data anticipated throughout 2023 and beyond.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Douglas Love speaking at the Needham Virtual Healthcare Conference?

Douglas Love will speak on April 18, 2023, at 1:30 p.m. ET.

What is the purpose of the fireside chat at the conference?

The chat will discuss Annexon's developments in complement medicines for autoimmune and neurodegenerative disorders.

How can I access the live webcast of the event?

The live webcast can be accessed under the 'Events & Presentations' section on Annexon's Investors page.

Will there be a replay of the conference presentation?

Yes, a replay will be archived on the Annexon website for 30 days after the event.

What are Annexon's main areas of focus?

Annexon focuses on diseases related to the classical complement pathway, targeting autoimmune, neurodegenerative, and ophthalmic conditions.

Keep reading